PubMed Health⌕ Search

Biomedical subjects

S Mlekodaj

Publications and source records attributed to S Mlekodaj.

At least 19 recordsLinked to original sources
PubMed1998

Inhibition of angiogenesis by sulindac and its sulfone metabolite (FGN-1): a potential mechanism for their antineoplastic properties.

The nonsteroidal antiinflammatory drug sulindac (sulfoxide) is known to cause regression and prevent recurrence of adenomas in patients with familial adenomatous polyposis. The mechanism of action does not appear to require inhibition of prostaglandin synthesis since the sulfone metabolite of sulindac (FGN-1) retains the antineoplastic properties of sulindac but lacks inhibitory effects on cyclooxygenase, types 1 and 2. FGN-1 has been shown to induce apoptosis in a variety of tumor cell lines, and selective apoptosis of neoplastic cells has been proposed to account for its antineoplastic properties. Since angiogenesis is necessary for tumor progression and may be related to apoptosis, it is possible that inhibition of angiogenesis may also contribute to the antineoplastic properties of sulindac or FGN-1. In order to test this possibility, cells derived from several different types of human lung tumors were grafted intradermally in Balb/c mice. Sulindac sulfoxide and its sulfide and sulfone metabolites were administered for 3 days orally, in a daily dose of 0.025-0.5 mg, and angiogenesis was measured after 72 h using a previously described method. The results showed that sulindac sulfoxide and sulfone statistically inhibited angiogenesis.

Adenocarcinoma↗
PubMed1997

Screening of angiogenesis inhibitors by modified tumor-induced angiogenesis (TIA) test in lung cancer.

Aberrant angiogenesis-the new vessels formation is a mandatory event in the process of tumor growth and expansion. Studies on mechanisms involved in tumor-induced angiogenesis (TIA) and on its possible inhibitors are needed in order to introduce in future new methods of tumor treatment. The aim of our study was to determine the usefulness of the modified cutaneous TIA (mice without immunosuppression) test for screening in vivo of the angiogenesis modifiers. In both models (classical and modified TIA) we demonstrated comparable angiogenesis activity following human lung cells inoculation and similar degree of neovascularization response inhibition caused by theobromine. We reported that in modified TIA model preincubation with theobromine significantly suppressed angiogenic potential of human lung cancer cells as well as the ability of those cells to produce proangiogenic cytokine-bFGF.

Adenocarcinoma↗
PubMed1997

[Five year survival of patients treated surgically for lung neoplasms].

The results of surgery for lung cancer performed in 1981 and respectively in 1991 were compared in regards to 5 years survival time. Most centers of thoracic surgery in Poland participated in the study. In 1981 728 patients underwent surgery for LC and in 1991-1141 had some kinds of lung resection for LC. The improvement rate of 17% in regards to 5 years survival time was achieved in the latter period.

Humans↗
PubMed1994

[Treatment of chronic empyemas in the pleural cavity].

The authors present the results of surgical treatment of chronic empyemas of the pleural cavity in 294 patients treated at the Surgical Department in the years 1980-1992. The methods of treatment are discussed taking in consideration the etiology of the empyemas, clinical presentation, coexistent diseases. In 86 patients (29.3%) decortication with partial resection of the lung was carried out (most often a lobe), in 123 patients (41.8%) a decortication was performed, in 8 (2.7%) thoracoplasty, in the remaining 41 (13.9%) drainage of the pleural cavity was carried out. Out of the 245 subjects treated surgically 3 (1.2%) died; in the remaining patients a full recovery was noted. A full recovery was noted in 22 (53.7%) out of the 41 treated with pleural cavity drainage. Eight patients with esophageal-pleural fistulas in the course of a advanced esophageal cancer died due to advanced malignancy. 11 were discharged with chronic drainage. The latter could not be treated surgically due to a existence of high risk factors.

Adult↗
PubMed1994

[Modern indications for surgical treatment of pulmonary tuberculosis and efficacy of using these methods].

The authors have shown the modern indications for surgical treatment of pulmonary tuberculosis and the results of such treatment in 217 patients. The main indications were: empyema in 58 patients, pulmonary hemorrhages in 18 cases, aspergillomas in tuberculosis caverns in 42 patients, post-tuberculosis stenoses of the bronchi in 9 cases, inefficient chemotherapy in atypical mycobacteriosis in 16, inefficient 12 months chemotherapy in 42 as judged by sputum positivity, peripheral round lesions judged to be tuberculomas in 32 cases.

Adult↗
PubMed1993

[Five year survival in patients with non small cell carcinoma of the lung treated surgically].

The late results of surgical treatment of non small cell lung cancer in 735 patients treated in the years 1981-1986 are presented. 59.3% of the patients with stage I disease are alive after 5 years; 43% with stage II and 23.6% with stage III. 326 (44.3%) out the initial number of 735 surgically treated patients have survived 5 years. 274 patient died in the course of local recurrencies and distal metastases, while 135 died due to nonmalignant causes.

Adult↗
PubMed1980

Peripheral blood lymphocytes and their subpopulations in lung carcinoma.

In 166 patients with lung carcinoma peripheral blood lymphocytes and their subpopulastions (AE-RFC, TE-RFC, EAC-RFC) were examined. In comparison with control--the mean values of the absolute counts of the blood lymphocytes did not show statistically significant changes in various stages of lung cancer. However, the count of active T lymphocytes as well as total T lymphocytes were slightly lowered in the stage I of the disease, and significantly decreased in stages II and III. The lowest decrease of T lymphocytes was found in adenocarcinoma and the greatest--in microcellular cancer.

Adenocarcinoma↗